A detailed history of Credit Suisse Ag transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Credit Suisse Ag holds 719,309 shares of CRSP stock, worth $33.8 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
719,309
Previous 876,145 17.9%
Holding current value
$33.8 Million
Previous $54.8 Million 10.61%
% of portfolio
0.05%
Previous 0.05%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$60.67 - $89.12 $9.52 Million - $14 Million
-156,836 Reduced 17.9%
719,309 $49 Million
Q4 2023

Feb 08, 2024

BUY
$38.62 - $72.18 $124,124 - $231,986
3,214 Added 0.37%
876,145 $54.8 Million
Q3 2023

Nov 13, 2023

SELL
$45.39 - $59.0 $2.21 Million - $2.87 Million
-48,725 Reduced 5.29%
872,931 $39.6 Million
Q2 2023

Aug 11, 2023

BUY
$43.47 - $67.77 $3.23 Million - $5.04 Million
74,383 Added 8.78%
921,656 $51.7 Million
Q1 2023

May 10, 2023

SELL
$41.0 - $56.12 $230,256 - $315,169
-5,616 Reduced 0.66%
847,273 $38.3 Million
Q4 2022

Feb 13, 2023

BUY
$39.19 - $65.67 $477,451 - $800,057
12,183 Added 1.45%
852,889 $34.7 Million
Q3 2022

Nov 10, 2022

SELL
$61.1 - $83.78 $5.07 Million - $6.95 Million
-82,965 Reduced 8.98%
840,706 $54.9 Million
Q2 2022

Aug 12, 2022

SELL
$43.23 - $73.83 $4.07 Million - $6.95 Million
-94,156 Reduced 9.25%
923,671 $56.1 Million
Q1 2022

May 16, 2022

SELL
$53.19 - $79.24 $4.02 Million - $5.99 Million
-75,625 Reduced 6.92%
1,017,827 $63.9 Million
Q4 2021

Feb 14, 2022

BUY
$70.09 - $111.29 $12.7 Million - $20.1 Million
180,911 Added 19.82%
1,093,452 $82.9 Million
Q3 2021

Nov 12, 2021

SELL
$110.2 - $156.64 $5.35 Million - $7.61 Million
-48,573 Reduced 5.05%
912,541 $102 Million
Q2 2021

Aug 16, 2021

BUY
$100.84 - $161.89 $4.28 Million - $6.86 Million
42,404 Added 4.62%
961,114 $156 Million
Q1 2021

May 14, 2021

BUY
$110.72 - $210.04 $13.9 Million - $26.3 Million
125,266 Added 15.79%
918,710 $112 Million
Q4 2020

Feb 12, 2021

BUY
$79.67 - $173.23 $7.26 Million - $15.8 Million
91,158 Added 12.98%
793,444 $121 Million
Q3 2020

Nov 13, 2020

SELL
$78.5 - $100.64 $1.85 Million - $2.38 Million
-23,624 Reduced 3.25%
702,286 $58.7 Million
Q2 2020

Aug 12, 2020

SELL
$38.5 - $76.05 $4.85 Million - $9.58 Million
-125,957 Reduced 14.79%
725,910 $53.3 Million
Q1 2020

May 13, 2020

BUY
$33.68 - $62.53 $4.4 Million - $8.16 Million
130,555 Added 18.1%
851,867 $36.1 Million
Q4 2019

Feb 12, 2020

SELL
$36.68 - $73.13 $312,366 - $622,775
-8,516 Reduced 1.17%
721,312 $43.9 Million
Q3 2019

Nov 12, 2019

SELL
$40.99 - $52.56 $2.81 Million - $3.61 Million
-68,644 Reduced 8.6%
729,828 $29.9 Million
Q2 2019

Aug 14, 2019

SELL
$35.45 - $48.2 $3.26 Million - $4.44 Million
-92,092 Reduced 10.34%
798,472 $37.6 Million
Q1 2019

May 14, 2019

BUY
$28.02 - $40.87 $3.24 Million - $4.73 Million
115,691 Added 14.93%
890,564 $31.8 Million
Q4 2018

Feb 13, 2019

BUY
$22.73 - $42.34 $4.06 Million - $7.57 Million
178,821 Added 30.0%
774,873 $22.1 Million
Q3 2018

Nov 13, 2018

BUY
$44.35 - $65.71 $9.49 Million - $14.1 Million
213,988 Added 56.01%
596,052 $26.4 Million
Q2 2018

Aug 14, 2018

SELL
$42.62 - $73.59 $2.77 Million - $4.78 Million
-64,984 Reduced 14.54%
382,064 $22.5 Million
Q1 2018

May 15, 2018

BUY
$23.52 - $58.17 $98,854 - $244,488
4,203 Added 0.95%
447,048 $20.4 Million
Q4 2017

Feb 14, 2018

BUY
$16.95 - $23.48 $6.15 Million - $8.52 Million
362,797 Added 453.22%
442,845 $10.4 Million
Q3 2017

Nov 14, 2017

BUY
$16.75 - $20.66 $804 - $991
48 Added 0.06%
80,048 $1.43 Million
Q2 2017

Aug 14, 2017

BUY
N/A
80,000
80,000 $1.28 Million

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.67B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.